Mylan settles with Warner Chilcott over Femcon

19 October 2011

US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it, along with Famy Care, has entered into a settlement agreement with Ireland-headquartered Warner Chilcott (Nasdaq: WCRX) resolving litigation related to the oral contraceptive Femcon Fe Chewable Tablets, known generically as norethindrone and ethinyl estradiol Tablets USP 0.4mg/0.035mg and ferrous fumarate tablets USP (Chewable), 75mg (28-Day Regimen).

Under the settlement agreement, the pending litigation has been dismissed and Mylan may begin to market and sell a generic version of Femcon Fe in the USA upon receipt of final product approval from the US Food and Drug Administration.

Additional details of the settlement are confidential, and the agreement itself is subject to review by the US Department of Justice and the Federal Trade Commission, said Mylan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK